Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Most Companies Still Mum On Device Tax Coping Strategies

This article was originally published in The Gray Sheet

Executive Summary

While some companies have started to reveal strategies to either soften the blow or to capitalize on the impending device excise tax, many have revealed little to no detail on their planned response.

You may also be interested in...



GPO Website Exposes Firms That Are Passing Device Tax On To Customers

The site Medical Device Tax Watch (www.devicetaxwatch.com) lists companies that the Healthcare Supply Chain Association says are “shifting the burden of the medical device excise tax ... directly to American hospitals and other health care providers.”

Tax Reform, Device Tax Get More Attention On The Hill

Comprehensive tax reform is a top priority of House Republicans this year, Ways and Means Chairman Dave Camp, R-Mich., said last week, providing a potential vehicle for device tax repeal. And the device tax received attention at a Democratic-controlled Senate Budget Hearing last week.

Device Trends To Watch In 2013

The prospective medical device tax, the continuing decline of venture investing, pricing challenges, austerity measures in Europe, and other headwinds continued to push against the medtech industry in 2012. But emerging clinical and geographic markets, along with an active M&A market, are providing the industry with some momentum going into 2013.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel